February 17, 2023Lung CancerOpen Access

Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial

View Full Paper

Ask AI

Bookmark

Abstract

This is the authors' abstract. We don't add key points for this paper.

The third-generation EGFR TKI osimertinib, with satisfying efficacy and acceptable safety profile, could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lv et al. (2023) studied this question.

synapsesocial.com/papers/69dab5814a1e15904c835d0a https://doi.org/10.1016/j.lungcan.2023.02.011

View Full Paper

Ask AI

Bookmark

Abstract

This is the authors' abstract. We don't add key points for this paper.

The third-generation EGFR TKI osimertinib, with satisfying efficacy and acceptable safety profile, could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC.

Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial

Abstract

Discussion

Cite This Study

Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial

Abstract

Discussion

Cite This Study

Keep reading

Keep reading